Results 121 to 130 of about 1,239,389 (314)

A comparison of respiratory oscillometry and spirometry in idiopathic pulmonary fibrosis: performance time, symptom burden and test–retest reliability

ERJ Open Research
Study question In large multinational patient surveys, spirometry (which requires repeated, reproducible maximal efforts) can be associated with cough, breathlessness and tiredness, particularly in those with idiopathic pulmonary fibrosis (IPF ...
Suhani Patel, Karl P. Sylvester, Zhe Wu, Serena Rhamie, Peter Dickel, Toby M. Maher, Philip L. Molyneaux, Peter M.A. Calverley, William D-C. Man   +8 more
doaj   +1 more source

Lung function decline in COPD

, 2012
Claudio Tantucci, Denise ModinaUnit of Respiratory Medicine, Department of Medical and Surgical Sciences, University of Brescia, Brescia, ItalyAbstract: The landmark study of Fletcher and Peto on the natural history of tobacco smoke-related chronic ...
Modina D, Tantucci C
core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

HIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium

, 2013
Background: While acute lung injury (ALI) contributes significantly to critical illness, it resolves spontaneously in many instances. The majority of patients experiencing ALI require mechanical ventilation.
Christoph H Borchers, Michel Mittelbronn, Thomas Packard, Kominsky, Douglas J., Bonney, Megan, Packard, Thomas, Michel Mittelbronn (307400), Eltzschig, Holger K., Holger K Eltzschig, Kelley Brodsky (448211), Mariani, Thomas J., Borchers, Christoph H., Brodsky, Kelley, Christoph H. Borchers (159697), Thomas J. Mariani (11667), Han, Jun, Eckle, Tobias, Holger K. Eltzschig (37610), Mittelbronn, Michel Guy André, Megan Bonney (462424), Thomas J Mariani, Jun Han, Douglas J Kominsky, Douglas J. Kominsky (462426), Tobias Eckle, Jun Han (231645), Kelley Brodsky, Megan Bonney, Tobias Eckle (65757), Thomas Packard (462425)   +29 more
core   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.

, 2011
Background Relationships between improvements in lung function and other clinical outcomes in chronic obstructive pulmonary disease (COPD) are not documented extensively.
Pinault, Gregory, Nedelman Jerry, Jones, Paul W, James F Donohue, Jones, PW, Donohue, JF, Steve Pascoe, Pinault Gregory, Pascoe Steve, Donohue James F, Lassen Cheryl, Pinault, G, Pascoe, S, Nedelman, J, Pascoe, Steve, Jerry Nedelman, Paul W Jones, Lassen, Cheryl, Jones Paul W, Cheryl Lassen, Gregory Pinault, Nedelman, Jerry, Donohue, James F, Lassen, C   +23 more
core   +1 more source

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

FEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen, Qianqian Cui, Zhongyun Lan, Yingjun Wang, Shuaiying Zhao, Wenxuan Feng, Yunfeng Liu, Qiting Huang, Dongna Zhang, Jianfeng Xu   +9 more
wiley   +1 more source

Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion

FEBS Open Bio, EarlyView.
This paper reveals how human lactoferrin–albumin fusion (hLF‐HSA) potently suppresses lung adenocarcinoma cell migration. hLF‐HSA upregulates NHE7, leading to Golgi alkalization, disruption of the Golgi secretome, downregulation of MMP1, and reversal of EMT. These findings suggest a novel Golgi‐targeting strategy to suppress cancer cell migration.
Hana Nopia, Masahiro Kimura, Daisuke Kurimoto, Atsushi Sato   +3 more
wiley   +1 more source

Role of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Inflammation and Pathogen-Associated Interactions

Journal of Innate Immunity
Background: Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is known as a major receptor for oxidized low-density lipoproteins (oxLDL) and plays a significant role in the genesis of atherosclerosis.
Sarah Truthe, Tilman E. Klassert, Stefan Schmelz, Danny Jonigk, Wulf Blankenfeldt, Hortense Slevogt   +5 more
doaj   +1 more source